Ruggiero Salvatore L, Woo Sook-Bin
Department of Oral and Maxillofacial Surgery, Stony Brook School of Dental Medicine, Stony Brook, NY, USA.
Dent Clin North Am. 2008 Jan;52(1):111-28, ix. doi: 10.1016/j.cden.2007.09.002.
In 2003 and 2004, the first reports of patients who developed necrosis of the jawbones while taking biophosphonates appeared in literature; most patients were on this drug for treatment of cancer and some osteoporosis. Since then, more than 500 cases have been identified and the number of these cases continues to grow. This article reviews the action of bisphosphonates, the condition called bisphosphonate-associated osteonecrosis of the jaws, strategies to minimize occurrence, and treatment of this condition.
2003年和2004年，关于服用双膦酸盐类药物时出现颌骨坏死患者的首批报告出现在文献中；大多数患者服用该药物用于治疗癌症和某些骨质疏松症。从那时起，已确认了500多例病例，且病例数量仍在持续增加。本文综述了双膦酸盐类药物的作用、称为双膦酸盐相关颌骨坏死的病症、将其发生几率降至最低的策略以及该病症的治疗方法。
